Base de dados : MEDLINE
Pesquisa : D20.215.894.200 [Categoria DeCS]
Referências encontradas : 11802 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1181 ir para página                         

  1 / 11802 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28468915
[Au] Autor:Mei Y; Zhao L; Liu Y; Gong H; Song Y; Lei L; Zhu Y; Jin Z; Ma S; Hu B; Sun Q; Liu H
[Ad] Endereço:Institute of Blood and Marrow Transplantation, Department of Hematology, Collaborative Innovation Center of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, P.R. China.
[Ti] Título:Combining DNA Vaccine and AIDA-1 in Attenuated Activates Tumor-Specific CD4 and CD8 T-cell Responses.
[So] Source:Cancer Immunol Res;5(6):503-514, 2017 Jun.
[Is] ISSN:2326-6074
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Stimulation of tumor-specific responses in both CD4 and CD8 T cells has been a challenge for effective tumor vaccines. We designed a vaccine vector containing the AIDA-1 autotransporter and DNA vaccine elements, generating a murine melanoma vaccine that was delivered by the attenuated strain SL7207. Growth of murine subcutaneous melanoma was significantly inhibited by intranasal immunization with the tumor vaccine. The vaccine activated tumor-specific CD4 and CD8 T-cell responses, with increased T-cell proliferation, tumor antigen-specific Th1 cytokine production, increased percentages of tetramer positive cells, and cytotoxicity. CD4 or CD8 T-cell depletion resulted in the loss of antitumor activity of the tumor vaccine, suggesting that the efficacy of the vaccine was dependent on both CD4 and CD8 T cells. Lung metastasis of the tumor was also inhibited by vaccine treatment. Similarly, the percentages of tumor-specific Th1 cytokine production by CD4 and CD8 T cells in the spleen, tumor, and bronchoalveolar lavage were increased after vaccine treatment. Tumor-specific proliferation of CD4 and CD8 T cells was also promoted by the vaccine. Tetramer staining and cytotoxicity assay showed enhanced tumor-specific CD8 T-cell response after vaccine treatment. Therefore, the tumor vaccine could activate both tumor-specific CD4 and CD8 T-cell responses. This vaccine strategy may be widely applicable to the development of oral or nasal vaccines against tumors. .
[Mh] Termos MeSH primário: Linfócitos T CD4-Positivos/imunologia
Linfócitos T CD8-Positivos/imunologia
Vacinas Anticâncer/administração & dosagem
Neoplasias/imunologia
Salmonella
Vacinas de DNA/administração & dosagem
[Mh] Termos MeSH secundário: Animais
Proteínas de Transporte
Linhagem Celular Tumoral
Feminino
Camundongos Endogâmicos C57BL
Neoplasias/patologia
Neoplasias/terapia
Salmonella/genética
Carga Tumoral
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (ANKS1B protein, human); 0 (Cancer Vaccines); 0 (Carrier Proteins); 0 (Vaccines, DNA)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.1158/2326-6066.CIR-16-0240-T


  2 / 11802 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28460478
[Au] Autor:Vo MC; Nguyen-Pham TN; Lee HJ; Jaya Lakshmi T; Yang S; Jung SH; Kim HJ; Lee JJ
[Ad] Endereço:Research Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Hwasun, Jeollanamdo, Republic of Korea.
[Ti] Título:Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model.
[So] Source:Oncotarget;8(16):27252-27262, 2017 Apr 18.
[Is] ISSN:1949-2553
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In this study, we investigated efficacy of lenalidomide in combination with tumor antigen-loaded dendritic cells (DCs) in murine colon cancer model. MC-38 cell lines were injected subcutaneously to establish colon cancer-bearing mice. After tumor growth, lenalidomide (50 mg/kg/day) was injected intraperitoneally on 3 consecutive days in combination with tumor antigen-loaded DC vaccination on days 8, 12, 16, and 20. The tumor antigen-loaded DCs plus lenalidomide combination treatment exhibited a significant inhibition of tumor growth compared with the other groups. These effects were associated with a reduction in immune suppressor cells, such as myeloid-derived suppressor cells and regulatory T cells, with the induction of immune effector cells, such as natural killer cells, CD4+ T cells and CD8+ T cells in spleen, and with the activation of cytotoxic T lymphocytes and NK cells. This study suggests that a combination of tumor antigen-loaded DC vaccination and lenalidomide synergistically enhanced antitumor immune response in the murine colon cancer model, by inhibiting the generation of immune suppressive cells and recovery of effector cells, and demonstrated superior polarization of Th1/Th2 balance in favor of Th1 immune response. This combination approach with DCs and lenalidomide may provide a new therapeutic option to improve the treatment of colon cancer.
[Mh] Termos MeSH primário: Neoplasias do Colo/imunologia
Neoplasias do Colo/patologia
Células Dendríticas/imunologia
Imunidade
Talidomida/análogos & derivados
[Mh] Termos MeSH secundário: Animais
Antígenos de Neoplasias/imunologia
Vacinas Anticâncer/administração & dosagem
Vacinas Anticâncer/imunologia
Linhagem Celular Tumoral
Sobrevivência Celular/efeitos dos fármacos
Neoplasias do Colo/genética
Neoplasias do Colo/terapia
Terapia Combinada
Citocinas/biossíntese
Células Dendríticas/metabolismo
Modelos Animais de Doenças
Feminino
Expressão Gênica
Imunidade/efeitos dos fármacos
Imunoterapia
Células Matadoras Naturais/imunologia
Células Matadoras Naturais/metabolismo
Camundongos
Linfócitos T Citotóxicos/efeitos dos fármacos
Linfócitos T Citotóxicos/imunologia
Linfócitos T Citotóxicos/metabolismo
Linfócitos T Reguladores/efeitos dos fármacos
Linfócitos T Reguladores/imunologia
Linfócitos T Reguladores/metabolismo
Talidomida/farmacologia
Vacinação
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, Neoplasm); 0 (Cancer Vaccines); 0 (Cytokines); 4Z8R6ORS6L (Thalidomide); F0P408N6V4 (lenalidomide)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE
[do] DOI:10.18632/oncotarget.15917


  3 / 11802 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27773685
[Au] Autor:Fehniger TA; Cooper MA
[Ad] Endereço:Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA. Electronic address: tfehnige@wustl.edu.
[Ti] Título:Harnessing NK Cell Memory for Cancer Immunotherapy.
[So] Source:Trends Immunol;37(12):877-888, 2016 12.
[Is] ISSN:1471-4981
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Due to their ability to kill cancer cells and produce proinflammatory cytokines, natural killer (NK) cells have long been of clinical interest for their antitumor properties. The recent discovery of NK cell memory demonstrates that NK cell functions, and potentially antitumor responses, can be enhanced long term. Following nonspecific activation with the cytokines IL-12, IL-15, and IL-18 or in response to antigens or cytomegalovirus (CMV), human and mouse NK cells exhibit stable, enhanced functional responses with phenotypic and molecular changes. Here we review mechanisms driving the differentiation of NK cell memory-like properties, evidence for antitumor activity, and the challenges and opportunities in harnessing memory-like NK cells for cancer immunotherapy.
[Mh] Termos MeSH primário: Vacinas Anticâncer/imunologia
Memória Imunológica
Imunoterapia Adotiva/métodos
Células Matadoras Naturais/imunologia
Subpopulações de Linfócitos/imunologia
Neoplasias/terapia
[Mh] Termos MeSH secundário: Animais
Diferenciação Celular
Citocinas/metabolismo
Citomegalovirus/imunologia
Citotoxicidade Imunológica
Seres Humanos
Mediadores da Inflamação/metabolismo
Células Matadoras Naturais/transplante
Ativação Linfocitária
Subpopulações de Linfócitos/transplante
Camundongos
Neoplasias/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Cancer Vaccines); 0 (Cytokines); 0 (Inflammation Mediators)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  4 / 11802 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28456076
[Au] Autor:Yang Z; Xu M; Jia Z; Zhang Y; Wang L; Zhang H; Wang J; Song M; Zhao Y; Wu Z; Zhao L; Yin Z; Hong Z
[Ad] Endereço:National Key Laboratory of Medical Chemical Biology & Tianjin Key Laboratory of Protein Science, Nankai University, Tianjin, 300071, China.
[Ti] Título:A novel antigen delivery system induces strong humoral and CTL immune responses.
[So] Source:Biomaterials;134:51-63, 2017 Jul.
[Is] ISSN:1878-5905
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:New strategies with the ability to enhance both the humoral and cellular immune responses remain a priority for the development of future therapeutic cancer vaccines. In this study, we took advantage of ß-glucan particles (GPs) derived from Saccharomyces cerevisiae baker's yeast and a novel reverse micro-emulsion method to prepare an antigen-loaded GP carrier system for dendritic cell (DC) specific antigen delivery, followed by careful evaluation of the immune functions of the prepared particles in initiating both the humoral and cellular immune responses through in vitro and in vivo experiments. The prepared particles greatly promoted DC activation and cytokine production and cross presented the antigen to CD8 cells, inducing very strong OVA specific humoral and cellular immune responses. Treatment with these particles significantly prevented the growth of implanted EG7-OVA tumors in a prophylactic and pre-established tumor model. These results suggest that our strategy may be able to be utilized as a promising platform for cancer immunotherapy.
[Mh] Termos MeSH primário: Imunidade Celular/fisiologia
Imunidade Humoral/fisiologia
Neoplasias/imunologia
[Mh] Termos MeSH secundário: Animais
Antígenos/administração & dosagem
Antígenos/imunologia
Vacinas Anticâncer/imunologia
Células Dendríticas/imunologia
Imunoterapia/métodos
Camundongos
Camundongos Endogâmicos C57BL
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens); 0 (Cancer Vaccines)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170430
[St] Status:MEDLINE


  5 / 11802 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27775991
[Au] Autor:Kan B; Yang L; Wen YJ; Yang JR; Niu T; Li J; Deng HX; Wei W; Chen LG; Zhang Q; Wang W; Wei YQ
[Ad] Endereço:aState Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy bDepartment of Emergency, West China Hospital, Sichuan University, Chengdu cSchool of Pharmaceutical Sciences, Tsinghua University, Beijing dState Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Collaborative Innovation Center of Chemical Science and Engineering (Tianjin), Nankai University, Tianjin, People's Republic of China.
[Ti] Título:Irradiated VEGF164-modified tumor cell vaccine protected mice from the parental tumor challenge.
[So] Source:Anticancer Drugs;28(2):197-205, 2017 02.
[Is] ISSN:1473-5741
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Vascular endothelial growth factor (VEGF) is an important regulating molecule of angiogenesis in tumor formation and progression. Cancer cells always secrete VEGF to stimulate angiogenesis that facilitate growth and invasion of the tumor. In this study, we established a VEGF164 overexpressing LL/2 lung cancer cell model and found that the postirradiated VEGF164-modified tumor cells protected the host against the challenge with LL/2 wild-type tumor cells. Histochemical assay showed that there were large areas of tumor necrosis with macrophage infiltration in the mice vaccinated with the VEGF164-modified tumor vaccine. T-cells isolated from the vaccinated mice showed cytotoxicity against the parental tumor cells in a dose-dependent manner. Meanwhile, sera from the mice vaccinated with LL/2-VEGF164 showed higher titers of antibodies against parental tumor cells compared with the nonvaccinated groups. Our results indicated that VEGF164-modified tumor vaccine could modulate host antitumor immune response and hold therapeutic potential for cancer.
[Mh] Termos MeSH primário: Vacinas Anticâncer/imunologia
Imunoterapia Adotiva/métodos
Neoplasias Pulmonares/imunologia
Neoplasias Pulmonares/terapia
Fator A de Crescimento do Endotélio Vascular/administração & dosagem
[Mh] Termos MeSH secundário: Animais
Linfócitos T CD4-Positivos/imunologia
Linfócitos T CD8-Positivos/imunologia
Vacinas Anticâncer/genética
Relação Dose-Resposta Imunológica
Feminino
Neoplasias Pulmonares/genética
Neoplasias Pulmonares/metabolismo
Camundongos
Camundongos Endogâmicos C57BL
Linfócitos T Citotóxicos/imunologia
Transfecção
Fator A de Crescimento do Endotélio Vascular/biossíntese
Fator A de Crescimento do Endotélio Vascular/genética
Fator A de Crescimento do Endotélio Vascular/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Cancer Vaccines); 0 (Vascular Endothelial Growth Factor A); 0 (vascular endothelial growth factor A, mouse)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE
[do] DOI:10.1097/CAD.0000000000000447


  6 / 11802 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29327244
[Au] Autor:Menssen HD; Harnack U; Erben U; Neri D; Hirsch B; Dürkop H
[Ad] Endereço:Division of Hematology and Oncology, Campus Benjamin Franklin, Department of Medicine, Charité-Universitätsmedizin Berlin, Hindenburgdamm 30, 12203, Berlin, Germany. hans_dietrich.menssen@charite.de.
[Ti] Título:Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model.
[So] Source:J Cancer Res Clin Oncol;144(3):499-507, 2018 Mar.
[Is] ISSN:1432-1335
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To analyze the impact of TNFα or IL2 on human lymphocytes in vitro and the anti-tumor and immune-modifying effects of L19-IL2 and L19-TNFα on subcutaneously growing J558L myeloma in immunocompetent mice. METHODS: PBMCs from three healthy volunteers were incubated with IL2, TNFα, or with IL2 plus addition of TNFα (final 20 h). BALB/c J558L mice with subcutaneous tumors were treated with intravenous L19-TNFα plus L19-IL2, or controls. Tumor growth and intra- and peri-tumoral tissues were analyzed for micro-vessel density, necrosis, immune cell composition, and PD1 or PD-L1 expressing cells. RESULTS: Exposure of PBMC in vitro to IL2, TNFα, or to IL2 over 3 and 5 days plus TNFα for the final 20 h resulted in an approximately 50 and 75% reduction of the CD25low effector cell/CD25high Treg cell ratio, respectively, compared to medium control. IL2 or TNFα increased the proportion of CD4- CD25low effector lymphocytes while reducing the proportion of CD4+ CD25low Teff cells. In the J558L myeloma model, tumor eradication was observed in 58, 42, 25, and 0% of mice treated with L19-TNFα plus L19-IL2, L19-TNFα, L19-IL2, and PBS, respectively. L19-TNFα/L19-IL2 combination caused tumor necrosis, capillary density doubling, peri-tumoral T cell and PD1+ T cell reduction (- 50%), and an increase in PD-L1+ myeloma cells. CONCLUSION: IL2, TNFα, or IL2 plus TNFα (final 20 h) increased the proportion of CD4- CD25low effector lymphocytes possibly indicating immune activation. L19-TNFα/L19-IL2 combination therapy eradicated tumors in J558L myeloma BALB/c mice likely via TNFα-induced tumor necrosis and L19-TNFα/L19-IL2-mediated local cellular immune reactions.
[Mh] Termos MeSH primário: Inibidores da Angiogênese/uso terapêutico
Anticorpos Monoclonais/uso terapêutico
Imunoterapia/métodos
Interleucina-2/uso terapêutico
Mieloma Múltiplo/terapia
Neovascularização Patológica/tratamento farmacológico
Fator de Necrose Tumoral alfa/uso terapêutico
[Mh] Termos MeSH secundário: Animais
Vacinas Anticâncer/uso terapêutico
Linhagem Celular Tumoral
Sistemas de Liberação de Medicamentos
Feminino
Imunotoxinas/uso terapêutico
Camundongos
Camundongos Endogâmicos BALB C
Mieloma Múltiplo/imunologia
Mieloma Múltiplo/patologia
Linfócitos T Reguladores/efeitos dos fármacos
Linfócitos T Reguladores/imunologia
Transplante Isogênico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Angiogenesis Inhibitors); 0 (Antibodies, Monoclonal); 0 (Cancer Vaccines); 0 (Immunotoxins); 0 (Interleukin-2); 0 (Tumor Necrosis Factor-alpha)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180113
[St] Status:MEDLINE
[do] DOI:10.1007/s00432-017-2564-6


  7 / 11802 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29420276
[Au] Autor:Kvistborg P; Yewdell JW
[Ad] Endereço:Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, Netherlands. p.kvistborg@nki.nl.
[Ti] Título:Enhancing responses to cancer immunotherapy.
[So] Source:Science;359(6375):516-517, 2018 02 02.
[Is] ISSN:1095-9203
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Imunoterapia
Neoplasias
[Mh] Termos MeSH secundário: Vacinas Anticâncer
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., INTRAMURAL; COMMENT
[Nm] Nome de substância:
0 (Cancer Vaccines)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180209
[St] Status:MEDLINE
[do] DOI:10.1126/science.aar6574


  8 / 11802 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28465452
[Au] Autor:Finn OJ
[Ad] Endereço:Department of Immunology, University of Pittsburgh School of Medicine and the University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania. ojfinn@pitt.edu.
[Ti] Título:Human Tumor Antigens Yesterday, Today, and Tomorrow.
[So] Source:Cancer Immunol Res;5(5):347-354, 2017 May.
[Is] ISSN:2326-6074
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The question of whether human tumors express antigens that can be recognized by the immune system has been answered with a resounding YES. Most were identified through spontaneous antitumor humoral and cellular immune responses found in cancer patients and include peptides, glycopeptides, phosphopeptides, viral peptides, and peptides resulting from common mutations in oncogenes and tumor-suppressor genes, or common gene fusion events. Many have been extensively tested as candidates for anticancer vaccines. More recently, attention has been focused on the potentially large number of unique tumor antigens, mutated neoantigens, that are the predicted products of the numerous mutations revealed by exome sequencing of primary tumors. Only a few have been confirmed as targets of spontaneous immunity and immunosurveillance, and even fewer have been tested in preclinical and clinical settings. The field has been divided for a long time on the relative importance of shared versus mutated antigens in tumor surveillance and as candidates for vaccines. This question will eventually need to be answered in a head to head comparison in well-designed clinical trials. One advantage that shared antigens have over mutated antigens is their potential to be used in vaccines for primary cancer prevention. .
[Mh] Termos MeSH primário: Antígenos de Neoplasias/imunologia
[Mh] Termos MeSH secundário: Animais
Vacinas Anticâncer
Seres Humanos
Neoplasias/imunologia
Neoplasias/prevenção & controle
Neoplasias/terapia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antigens, Neoplasm); 0 (Cancer Vaccines)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.1158/2326-6066.CIR-17-0112


  9 / 11802 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29298343
[Au] Autor:Choi YJ; Park SJ; Park YS; Park HS; Yang KM; Heo K
[Ad] Endereço:Research Center, Dongnam Institute of Radiological & Medical Sciences, Busan, Republic of Korea.
[Ti] Título:EpCAM peptide-primed dendritic cell vaccination confers significant anti-tumor immunity in hepatocellular carcinoma cells.
[So] Source:PLoS One;13(1):e0190638, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Cancer stem-like cells (CSCs) may play a key role in tumor initiation, self-renewal, differentiation, and resistance to current treatments. Dendritic cells (DCs) play a vital role in host immune reactions as well as antigen presentation. In this study, we explored the suitability of using CSC peptides as antigen sources for DC vaccination against human breast cancer and hepatocellular carcinoma (HCC) with the aim of achieving CSC targeting and enhancing anti-tumor immunity. CD44 is used as a CSC marker for breast cancer and EpCAM is used as a CSC marker for HCC. We selected CD44 and EpCAM peptides that bind to HLA-A2 molecules on the basis of their binding affinity, as determined by a peptide-T2 binding assay. Our data showed that CSCs express high levels of tumor-associated antigens (TAAs) as well as major histocompatibility complex (MHC) molecules. Pulsing DCs with CD44 and EpCAM peptides resulted in the efficient generation of mature DCs (mDCs), thus enhancing T cell stimulation and generating potent cytotoxic T lymphocytes (CTLs). The activation of CSC peptide-specific immune responses by the DC vaccine in combination with standard chemotherapy may provide better clinical outcomes in advanced carcinomas.
[Mh] Termos MeSH primário: Vacinas Anticâncer/uso terapêutico
Carcinoma Hepatocelular/terapia
Células Dendríticas/imunologia
Molécula de Adesão da Célula Epitelial/administração & dosagem
Neoplasias Hepáticas/terapia
Fragmentos de Peptídeos/administração & dosagem
[Mh] Termos MeSH secundário: Animais
Vacinas Anticâncer/imunologia
Carcinoma Hepatocelular/imunologia
Linhagem Celular Tumoral
Ensaio de Imunoadsorção Enzimática
Molécula de Adesão da Célula Epitelial/química
Feminino
Antígeno HLA-A2/imunologia
Xenoenxertos
Seres Humanos
Receptores de Hialuronatos/imunologia
Neoplasias Hepáticas/imunologia
Camundongos
Camundongos Endogâmicos BALB C
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Cancer Vaccines); 0 (EPCAM protein, human); 0 (Epithelial Cell Adhesion Molecule); 0 (HLA-A2 Antigen); 0 (Hyaluronan Receptors); 0 (Peptide Fragments)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180104
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0190638


  10 / 11802 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28459074
[Au] Autor:Rosenthal KS; Stone S; Koski G; Zimmerman DH
[Ad] Endereço:College of Medicine, Roseman University of Health Sciences, 10530 Discovery Drive, Las Vegas, NV 89135, USA.
[Ti] Título:LEAPS Vaccine Incorporating HER-2/neu Epitope Elicits Protection That Prevents and Limits Tumor Growth and Spread of Breast Cancer in a Mouse Model.
[So] Source:J Immunol Res;2017:3613505, 2017.
[Is] ISSN:2314-7156
[Cp] País de publicação:Egypt
[La] Idioma:eng
[Ab] Resumo:The prototype J-LEAPS T cell vaccine for HER-2/neu breast cancer (J-HER) consists of the murine HER-2/neu H-2 CD8 T cell epitope covalently attached through a triglycine linker to the J-immune cell binding ligand (ICBL) (human 2 microglobulin peptide). The J-ICBL was chosen for its potential to promote Th1/Tc1 responses. In this proof-of-concept study, the ability of J-HER to prevent or treat cancer was tested in the TUBO cell-challenged BALB/c mouse model for HER-2/neu-expressing tumors. The J-HER vaccine was administered as an emulsion in Montanide ISA-51 without the need for a more potent adjuvant. When administered as a prophylactic vaccination before tumor challenge, J-HER protected against tumor development for at least 48 days. Despite eliciting protection, antibody production in J-HER-immunized, TUBO-challenged mice was less than that in unimmunized mice. More importantly, therapeutic administration of J-HER one week after challenge with TUBO breast cancer cells limited the spread of the tumors and the morbidity and the mortality in the challenged mice. The ability to elicit responses that prevent spread of the TUBO tumor by J-HER suggests its utility as a neoimmunoadjuvant therapy to surgery. Individual or mixtures of J-LEAPS vaccines can be readily prepared to include different CD8 T cell epitopes to optimize tumor therapy and customize treatment for individuals with different HLA types.
[Mh] Termos MeSH primário: Vacinas Anticâncer
Neoplasias Mamárias Experimentais/prevenção & controle
Neoplasias Mamárias Experimentais/terapia
[Mh] Termos MeSH secundário: Animais
Neoplasias da Mama/genética
Neoplasias da Mama/imunologia
Neoplasias da Mama/prevenção & controle
Neoplasias da Mama/terapia
Linfócitos T CD8-Positivos/imunologia
Vacinas Anticâncer/genética
Vacinas Anticâncer/imunologia
Vacinas Anticâncer/uso terapêutico
Linhagem Celular Tumoral
Modelos Animais de Doenças
Progressão da Doença
Epitopos de Linfócito T/imunologia
Feminino
Genes erbB-2
Imunoglobulina G/sangue
Neoplasias Mamárias Experimentais/imunologia
Neoplasias Mamárias Experimentais/patologia
Camundongos
Camundongos Endogâmicos BALB C
Metástase Neoplásica/prevenção & controle
Estudo de Prova de Conceito
Linfócitos T Citotóxicos/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cancer Vaccines); 0 (Epitopes, T-Lymphocyte); 0 (Immunoglobulin G)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE
[do] DOI:10.1155/2017/3613505



página 1 de 1181 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde